此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery

2026年7月29日 更新者:Meliz Kneebone、Final International University

Comparison of Postoperative Effects of PRF and Corticosteroid Treatments in Impacted Third Molar Surgery

This prospective, randomized interventional study aims to compare the postoperative effects of standard treatment (control), platelet-rich fibrin (PRF), and PRF combined with corticosteroid treatment in patients undergoing impacted mandibular third molar surgery. A total of 60 participants will be randomly assigned to one of three treatment groups according to the study protocol. Postoperative pain, facial swelling, and trismus will be evaluated on postoperative days 1, 2, 3, and 7. The findings of this study are expected to provide evidence regarding the effectiveness of PRF alone and PRF combined with corticosteroid treatment in reducing postoperative complications following impacted mandibular third molar surgery.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Nicosia、塞浦路斯、2323
        • 招聘中
        • Final International University Faculty of Dentistry
        • 接触:
        • 首席研究员:
          • Meliz Kneebone, DDS

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Patients aged 18 years and older.
  • Patients with good general health
  • Patients with complete clinical and radiographic examination (panoramic radiograph/CBCT if applicable)
  • Patients willing and able to attend all postoperative follow-up visits

Exclusion Criteria:

  • Patients with systemic diseases that may impair wound healing (e.g., uncontrolled diabetes, immunodeficiency).
  • Pregnant or breastfeeding women.
  • Patients with acute infection, abscess, or pericoronitis at the surgical site.
  • Patients with a history of allergy or contraindication to corticosteroids, local anesthetics, or prescribed medications.
  • Patients using corticosteroids, anticoagulants, immunosuppressive drugs, or bisphosphonates.
  • Patients with bleeding disorders.
  • Patients with previous radiotherapy to the head and neck region.
  • Patients unable or unwilling to comply with the study protocol or attend follow-up visits.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard Postoperative Treatment (Control)
Participants receive standard postoperative treatment following impacted mandibular third molar surgery, including amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash. No platelet-rich fibrin (PRF) or corticosteroid is administered.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
实验性的:Platelet-Rich Fibrin (PRF)
Participants receive platelet-rich fibrin (PRF) placed into the extraction socket in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
实验性的:Platelet-Rich Fibrin Plus Corticosteroid
Participants receive platelet-rich fibrin (PRF) placement into the extraction socket followed by intramuscular corticosteroid administration, in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
Dexamethasone (8 mg/2 mL) administered as a single intramuscular injection immediately after impacted mandibular third molar surgery in addition to platelet-rich fibrin (PRF), according to the study protocol.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Postoperative Pain
大体时间:Postoperative Days 1, 2, 3, and 7
Postoperative pain assessed using a 10-cm Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable.
Postoperative Days 1, 2, 3, and 7
Postoperative Swelling
大体时间:Postoperative Days 1, 2, 3, and 7
Postoperative facial swelling assessed using a flexible measuring tape by recording the linear distances from the tragus to the pogonion (chin point), the tragus to the corner of the mouth, and the lateral canthus of the eye to the angle of the mandible.
Postoperative Days 1, 2, 3, and 7
Trismus
大体时间:Postoperative Days 1, 2, 3, and 7
Trismus assessed by measuring the maximum interincisal mouth opening (mm) using a digital caliper.
Postoperative Days 1, 2, 3, and 7

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月3日

初级完成 (估计的)

2026年8月1日

研究完成 (估计的)

2026年8月1日

研究注册日期

首次提交

2026年7月28日

首先提交符合 QC 标准的

2026年7月29日

首次发布 (实际的)

2026年8月3日

研究记录更新

最后更新发布 (实际的)

2026年8月3日

上次提交的符合 QC 标准的更新

2026年7月29日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the study was conducted as part of an academic thesis, and there is no institutional plan for sharing de-identified participant-level data.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅